Plasma circulating tumor DNA (ctDNA) enables non-invasive monitoring of metastatic cancer. However, the detection of low tumor content (TC) via tumor tissue-agnostic approaches remains challenging. We introduce METER, a computational strategy exploiting tumor-type specific DNA methylation patterns for sensitive ctDNA detection, accurate quantification, and subtyping from plasma low-pass (0.5-1x) whole-methylome sequencing. In longitudinal samples from metastatic breast cancer patients, METER demonstrated a stronger association with clinical outcomes than both state-of-the-art ctDNA methods and matched circulating tumor cell (CTC) counts, even at TC below 3%. METER (https://github.com/caos-lab-unifi/METER) integrates TC estimation and subtyping in a single framework, enabling sensitive and accurate analyses for precision oncology.
Building similarity graph...
Analyzing shared references across papers
Loading...
Marta Paoli
Francesca Galardi
Agostina Nardone
Genome Medicine
University of Florence
University of Trento
Ospedale SS. Annunziata
Building similarity graph...
Analyzing shared references across papers
Loading...
Paoli et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69a76079c6e9836116a2d3d3 — DOI: https://doi.org/10.1186/s13073-026-01603-3